Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Early fluctuations in busulfan levels with therapeutic dose monitoring during allogeneic stem cell transplantation: do they matter?

Jain T, Kunze KL, Khetarpal BK, McCallen MR, Betcher JA, Ofori HT, Khera N, Slack JL, Leis JF, Sproat LZ, Noel P, Palmer J.

Leuk Lymphoma. 2019 Aug;60(8):2034-2041. doi: 10.1080/10428194.2018.1562183. Epub 2019 Jan 10.

PMID:
30626239
2.

Single dose versus multiple doses of rituximab for preemptive therapy of Epstein-Barr virus reactivation after hematopoietic cell transplantation.

Jain T, Kosiorek HE, Grys TE, Kung ST, Shah VS, Betcher JA, Slack JL, Leis JF, Khera N, Noel P, Palmer JM, Sproat LZ.

Leuk Lymphoma. 2019 Jan;60(1):110-117. doi: 10.1080/10428194.2018.1459603. Epub 2018 Jul 6.

PMID:
29979906
3.

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.

DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Swords R, Collins RH, Mannis GN, Pollyea DA, Donnellan W, Fathi AT, Pigneux A, Erba HP, Prince GT, Stein AS, Uy GL, Foran JM, Traer E, Stuart RK, Arellano ML, Slack JL, Sekeres MA, Willekens C, Choe S, Wang H, Zhang V, Yen KE, Kapsalis SM, Yang H, Dai D, Fan B, Goldwasser M, Liu H, Agresta S, Wu B, Attar EC, Tallman MS, Stone RM, Kantarjian HM.

N Engl J Med. 2018 Jun 21;378(25):2386-2398. doi: 10.1056/NEJMoa1716984. Epub 2018 Jun 2.

4.

Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis.

Jain T, Kunze KL, Temkit M, Partain DK, Patnaik MS, Slack JL, Khera N, Hogan WJ, Roy V, Noel P, Leis JF, Sproat LZ, Fauble V, Mesa RA, Palmer J.

Bone Marrow Transplant. 2019 Feb;54(2):204-211. doi: 10.1038/s41409-018-0226-1. Epub 2018 May 24.

PMID:
29795431
5.

Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis.

Tefferi A, Partain DK, Palmer JM, Slack JL, Roy V, Hogan WJ, Litzow ML, Ketterling RP, Patnaik MM.

Am J Hematol. 2018 May;93(5):649-654. doi: 10.1002/ajh.25053. Epub 2018 Feb 24.

6.

Long-term impact of intrauterine neuroinflammation and treatment with magnesium sulphate and betamethasone: Sex-specific differences in a preterm labor murine model.

Thagard AS, Slack JL, Estrada SM, Kazanjian AA, Chan S, Burd I, Napolitano PG, Ieronimakis N.

Sci Rep. 2017 Dec 20;7(1):17883. doi: 10.1038/s41598-017-18197-x.

7.

Microbiologic yield of bronchoalveolar lavage specimens from stem cell transplant recipients.

Sakata KK, Klassen CL, Bollin KB, Grys TE, Slack JL, Wesselius LJ, Vikram HR.

Transpl Infect Dis. 2017 Jun;19(3). doi: 10.1111/tid.12684. Epub 2017 Apr 12.

PMID:
28218980
8.

Cytogenetic Evolution in Myeloid Neoplasms at Relapse after Allogeneic Hematopoietic Cell Transplantation: Association with Previous Chemotherapy and Effect on Survival.

Ertz-Archambault N, Kosiorek H, Slack JL, Lonzo ML, Greipp PT, Khera N, Kelemen K.

Biol Blood Marrow Transplant. 2017 May;23(5):782-789. doi: 10.1016/j.bbmt.2017.02.003. Epub 2017 Feb 9.

9.

Dynamics of leukemia stem-like cell extinction in acute promyelocytic leukemia.

Werner B, Gallagher RE, Paietta EM, Litzow MR, Tallman MS, Wiernik PH, Slack JL, Willman CL, Sun Z, Traulsen A, Dingli D.

Cancer Res. 2014 Oct 1;74(19):5386-96. doi: 10.1158/0008-5472.CAN-14-1210. Epub 2014 Jul 31.

10.

Protective effects of decay-accelerating factor on blast-induced neurotrauma in rats.

Li Y, Chavko M, Slack JL, Liu B, McCarron RM, Ross JD, Dalle Lucca JJ.

Acta Neuropathol Commun. 2013 Aug 16;1:52. doi: 10.1186/2051-5960-1-52.

11.

Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.

Slack JL, Dueck AC, Fauble VD, Sproat LO, Reeder CB, Noel P, Khera N, Betcher JA, Klein JL, Leis JF, Adams RH.

Biol Blood Marrow Transplant. 2013 Aug;19(8):1167-74. doi: 10.1016/j.bbmt.2013.05.001. Epub 2013 May 7.

12.

Decay-accelerating factor limits hemorrhage-instigated tissue injury and improves resuscitation clinical parameters.

Dalle Lucca JJ, Li Y, Simovic MO, Slack JL, Cap A, Falabella MJ, Dubick M, Lebeda F, Tsokos GC.

J Surg Res. 2013 Jan;179(1):153-67. doi: 10.1016/j.jss.2012.10.017. Epub 2012 Oct 29.

PMID:
23122671
13.

Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase.

Cherington C, Slack JL, Leis J, Adams RH, Reeder CB, Mikhael JR, Camoriano J, Noel P, Fauble V, Betcher J, Higgins MS, Gillette-Kent G, Tremblay LD, Peterson ME, Olsen JJ, Tibes R, Mesa RA.

Leuk Res. 2012 Sep;36(9):1147-51. doi: 10.1016/j.leukres.2012.04.021. Epub 2012 May 11.

PMID:
22578777
14.

Blast-induced moderate neurotrauma (BINT) elicits early complement activation and tumor necrosis factor α (TNFα) release in a rat brain.

Dalle Lucca JJ, Chavko M, Dubick MA, Adeeb S, Falabella MJ, Slack JL, McCarron R, Li Y.

J Neurol Sci. 2012 Jul 15;318(1-2):146-54. doi: 10.1016/j.jns.2012.02.002. Epub 2012 Apr 25.

PMID:
22537900
15.

Synthesis and screening of a haloacetamidine containing library to identify PAD4 selective inhibitors.

Jones JE, Slack JL, Fang P, Zhang X, Subramanian V, Causey CP, Coonrod SA, Guo M, Thompson PR.

ACS Chem Biol. 2012 Jan 20;7(1):160-5. doi: 10.1021/cb200258q. Epub 2011 Oct 21.

16.

The development of N-α-(2-carboxyl)benzoyl-N(5)-(2-fluoro-1-iminoethyl)-l-ornithine amide (o-F-amidine) and N-α-(2-carboxyl)benzoyl-N(5)-(2-chloro-1-iminoethyl)-l-ornithine amide (o-Cl-amidine) as second generation protein arginine deiminase (PAD) inhibitors.

Causey CP, Jones JE, Slack JL, Kamei D, Jones LE, Subramanian V, Knuckley B, Ebrahimi P, Chumanevich AA, Luo Y, Hashimoto H, Sato M, Hofseth LJ, Thompson PR.

J Med Chem. 2011 Oct 13;54(19):6919-35. doi: 10.1021/jm2008985. Epub 2011 Sep 16. Erratum in: J Med Chem. 2011 Nov 24;54(22):7942.

17.

Autodeimination of protein arginine deiminase 4 alters protein-protein interactions but not activity.

Slack JL, Jones LE Jr, Bhatia MM, Thompson PR.

Biochemistry. 2011 May 17;50(19):3997-4010. doi: 10.1021/bi200309e. Epub 2011 Apr 20.

18.

Development and use of clickable activity based protein profiling agents for protein arginine deiminase 4.

Slack JL, Causey CP, Luo Y, Thompson PR.

ACS Chem Biol. 2011 May 20;6(5):466-76. doi: 10.1021/cb1003515. Epub 2011 Feb 7.

19.

Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group.

Tallman MS, Kim HT, Montesinos P, Appelbaum FR, de la Serna J, Bennett JM, Deben G, Bloomfield CD, Gonzalez J, Feusner JH, Gonzalez M, Gallagher R, Miguel JD, Larson RA, Milone G, Paietta E, Rayon C, Rowe JM, Rivas C, Schiffer CA, Vellenga E, Shepherd L, Slack JL, Wiernik PH, Willman CL, Sanz MA.

Blood. 2010 Dec 16;116(25):5650-9. doi: 10.1182/blood-2010-06-288613. Epub 2010 Sep 21.

20.

Protein arginine deiminase 4: a target for an epigenetic cancer therapy.

Slack JL, Causey CP, Thompson PR.

Cell Mol Life Sci. 2011 Feb;68(4):709-20. doi: 10.1007/s00018-010-0480-x. Epub 2010 Aug 13.

21.

Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial.

Steensma DP, Baer MR, Slack JL, Buckstein R, Godley LA, Garcia-Manero G, Albitar M, Larsen JS, Arora S, Cullen MT, Kantarjian H.

J Clin Oncol. 2009 Aug 10;27(23):3842-8. doi: 10.1200/JCO.2008.19.6550. Epub 2009 Jun 15.

22.

Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML).

Wijermans PW, Rüter B, Baer MR, Slack JL, Saba HI, Lübbert M.

Leuk Res. 2008 Apr;32(4):587-91. Epub 2007 Sep 18.

PMID:
17881052
23.

Relapse of acute promyelocytic leukemia with PML-RARalpha mutant subclones independent of proximate all-trans retinoic acid selection pressure.

Gallagher RE, Schachter-Tokarz EL, Zhou DC, Ding W, Kim SH, Sankoorikal BJ, Bi W, Livak KJ, Slack JL, Willman CL.

Leukemia. 2006 Apr;20(4):556-62.

24.

Invasive filamentous fungal infections in allogeneic hematopoietic stem cell transplant recipients after recovery from neutropenia: clinical, radiologic, and pathologic characteristics.

Shaukat A, Bakri F, Young P, Hahn T, Ball D, Baer MR, Wetzler M, Slack JL, Loud P, Czuczman M, McCarthy PL, Walsh TJ, Segal BH.

Mycopathologia. 2005 Feb;159(2):181-8.

PMID:
15770441
25.

Thrombotic microangiopathy after allogeneic blood and marrow transplantation is associated with dose-intensive myeloablative conditioning regimens, unrelated donor, and methylprednisolone T-cell depletion.

Hahn T, Alam AR, Lawrence D, Ford L, Baer MR, Bambach B, Bernstein ZP, Czuczman MS, Silva J, Slack JL, Wetzler M, Becker J, McCarthy PL Jr.

Transplantation. 2004 Nov 27;78(10):1515-22.

PMID:
15599317
26.

Linezolid-resistant Enterococcus faecalis isolated from a cord blood transplant recipient.

Dibo I, Pillai SK, Gold HS, Baer MR, Wetzler M, Slack JL, Hazamy PA, Ball D, Hsiao CB, McCarthy PL Jr, Segal BH.

J Clin Microbiol. 2004 Apr;42(4):1843-5.

27.

Massive hyperdiploidy and tetraploidy in acute myelocytic leukemia and myelodysplastic syndrome.

Iyer RV, Sait SN, Matsui S, Block AW, Barcos M, Slack JL, Wetzler M, Baer MR.

Cancer Genet Cytogenet. 2004 Jan 1;148(1):29-34.

PMID:
14697638
28.

Simvastatin-fluconazole causing rhabdomyolysis.

Shaukat A, Benekli M, Vladutiu GD, Slack JL, Wetzler M, Baer MR.

Ann Pharmacother. 2003 Jul-Aug;37(7-8):1032-5.

PMID:
12841814
29.

Use of nonvolume-reduced (unmanipulated after thawing) umbilical cord blood stem cells for allogeneic transplantation results in safe engraftment.

Hahn T, Bunworasate U, George MC, Bir AS, Chinratanalab W, Alam AR, Bambach B, Baer MR, Slack JL, Wetzler M, Becker JL, McCarthy PL Jr.

Bone Marrow Transplant. 2003 Jul;32(2):145-50.

PMID:
12838278
30.

HLA-DR antigen-negative acute myeloid leukemia.

Wetzler M, McElwain BK, Stewart CC, Blumenson L, Mortazavi A, Ford LA, Slack JL, Barcos M, Ferrone S, Baer MR.

Leukemia. 2003 Apr;17(4):707-15.

PMID:
12682628
31.

Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129.

Gallagher RE, Yeap BY, Bi W, Livak KJ, Beaubier N, Rao S, Bloomfield CD, Appelbaum FR, Tallman MS, Slack JL, Willman CL.

Blood. 2003 Apr 1;101(7):2521-8. Epub 2002 Dec 5.

PMID:
12468436
32.

Advances in the management of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide.

Slack JL, Waxman S, Tricot G, Tallman MS, Bloomfield CD.

Oncologist. 2002;7 Suppl 1:1-13. Review.

33.

Pre-clinical validation of a novel, highly sensitive assay to detect PML-RARalpha mRNA using real-time reverse-transcription polymerase chain reaction.

Slack JL, Bi W, Livak KJ, Beaubier N, Yu M, Clark M, Kim SH, Gallagher RE, Willman CL.

J Mol Diagn. 2001 Nov;3(4):141-9.

34.

Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: possible beneficial use of low molecular weight heparin.

Simon M, Hahn T, Ford LA, Anderson B, Swinnich D, Baer MR, Bambach B, Bernstein SH, Bernstein ZP, Czuczman MS, Slack JL, Wetzler M, Herzig G, Schriber J, McCarthy PL Jr.

Bone Marrow Transplant. 2001 Mar;27(6):627-33.

35.

Current issues in the management of acute promyelocytic leukemia.

Slack JL, Rusiniak ME.

Ann Hematol. 2000 May;79(5):227-38. Review.

PMID:
10870476
36.

Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme.

Reddy P, Slack JL, Davis R, Cerretti DP, Kozlosky CJ, Blanton RA, Shows D, Peschon JJ, Black RA.

J Biol Chem. 2000 May 12;275(19):14608-14.

37.

Identification of B94 (TNFAIP2) as a potential retinoic acid target gene in acute promyelocytic leukemia.

Rusiniak ME, Yu M, Ross DT, Tolhurst EC, Slack JL.

Cancer Res. 2000 Apr 1;60(7):1824-9.

38.

Identification of two major sites in the type I interleukin-1 receptor cytoplasmic region responsible for coupling to pro-inflammatory signaling pathways.

Slack JL, Schooley K, Bonnert TP, Mitcham JL, Qwarnstrom EE, Sims JE, Dower SK.

J Biol Chem. 2000 Feb 18;275(7):4670-8.

39.

Molecular analysis and clinical outcome of adult APL patients with the type V PML-RARalpha isoform: results from intergroup protocol 0129.

Slack JL, Willman CL, Andersen JW, Li YP, Viswanatha DS, Bloomfield CD, Tallman MS, Gallagher RE.

Blood. 2000 Jan 15;95(2):398-403.

PMID:
10627441
40.

Thiotepa-associated cardiomyopathy during blood or marrow transplantation: association with the female sex and cardiac risk factors.

Alidina A, Lawrence D, Ford LA, Baer MR, Bambach B, Bernstein SH, Czuczman MS, Slack JL, Spangenthal E, Wetzler M, Barcos MP, Proulx GM, Anderson B, McCarthy PL Jr.

Biol Blood Marrow Transplant. 1999;5(5):322-7.

41.

Biology and treatment of acute progranulocytic leukemia.

Slack JL.

Curr Opin Hematol. 1999 Jul;6(4):236-40. Review.

PMID:
10400372
42.

The biology and treatment of acute progranulocytic leukemia.

Slack JL.

Curr Opin Oncol. 1999 Jan;11(1):9-13. Review.

PMID:
9914871
43.

The molecular biology of acute promyelocytic leukemia.

Slack JL, Gallagher RE.

Cancer Treat Res. 1999;99:75-124. Review.

PMID:
9891864
44.

An essential role for ectodomain shedding in mammalian development.

Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC, Russell WE, Castner BJ, Johnson RS, Fitzner JN, Boyce RW, Nelson N, Kozlosky CJ, Wolfson MF, Rauch CT, Cerretti DP, Paxton RJ, March CJ, Black RA.

Science. 1998 Nov 13;282(5392):1281-4.

45.

Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor.

Buxbaum JD, Liu KN, Luo Y, Slack JL, Stocking KL, Peschon JJ, Johnson RS, Castner BJ, Cerretti DP, Black RA.

J Biol Chem. 1998 Oct 23;273(43):27765-7.

46.

Expression and function of the megakaryocyte growth and development factor receptor in acute myeloid leukemia blasts.

Wetzler M, Bernstein SH, Baumann H, Fries KM, Stewart C, Blumenson L, Baer MR, Herzig GP, Bloomfield CD, Slack JL.

Leuk Lymphoma. 1998 Aug;30(5-6):415-31.

PMID:
9711904
48.

Association of PML-RAR alpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study.

Gallagher RE, Willman CL, Slack JL, Andersen JW, Li YP, Viswanatha D, Bloomfield CD, Appelbaum FR, Schiffer CA, Tallman MS, Wiernik PH.

Blood. 1997 Aug 15;90(4):1656-63.

PMID:
9269786
49.

Secondary cytogenetic changes in acute promyelocytic leukemia--prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study.

Slack JL, Arthur DC, Lawrence D, Mrózek K, Mayer RJ, Davey FR, Tantravahi R, Pettenati MJ, Bigner S, Carroll AJ, Rao KW, Schiffer CA, Bloomfield CD.

J Clin Oncol. 1997 May;15(5):1786-95.

PMID:
9164186
50.

A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells.

Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP.

Nature. 1997 Feb 20;385(6618):729-33.

PMID:
9034190

Supplemental Content

Loading ...
Support Center